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3172Objectives: The perioperative administration of pleomorphic statin drugs has been implicated in improving
outcomes after cardiac surgery. Adaptive autophagy is a highly conserved cellular process that allows for the
elimination of dysfunctional cell components in response to stress and survival under starving conditions. We
sought to investigate the effects of the statin drug atorvastatin on autophagy in ischemic and nonischemic
myocardia using a clinically relevant porcine model of metabolic syndrome.
Methods: Male Ossabaw swine were fed a regular diet (n ¼ 8), a high-cholesterol diet (n ¼ 8), or a
high-cholesterol diet with supplemental atorvastatin (1.5 mg/kg/d) (n ¼ 8). After 14 weeks, all animals
underwent surgical placement of an ameroid constrictor to the circumflex coronary artery to induce chronic
ischemia. Nonischemic and ischemic myocardia were harvested 6 months after initiation of the diet and
processed for Western blotting.
Results: In the nonischemic myocardium, Western blot results demonstrate that a high cholesterol diet resulted
in a statistically significant decrease in autophagy as indicated by an increase in mammalian target of rapamycin
and the accumulation of several essential autophagy markers, including Beclin-1, light chain 3B-I, and light
chain 3B-II. Atorvastatin supplementation prevented these changes and resulted in an increase in autophagy
as indicated by a decrease in autophagy flux marker P62. In the ischemic myocardium, atorvastatin had the
opposite effect, with a decrease in autophagy flux as indicated by an increase in p62 and an accumulation of light
chain 3B-I, light chain B-II, and lysosome-associated membrane protein 2.
Conclusions: Atorvastatin administration has differential effects on autophagy in ischemic and nonischemic
myocardia. In the setting of metabolic syndrome, atorvastatin stimulates autophagy in nonischemic myocardium
while partly inhibiting autophagy in ischemic myocardium. The differential regulation on autophagy may, in
part, explain the cardioprotective effect of statins in both ischemic and nonischemic myocardia, and these
findings may have implications in the setting of cardiac surgery. (J Thorac Cardiovasc Surg 2014;148:3172-8)See related commentary on pages 3178-9.Autophagy is an adaptive and essential cellular process that
eliminates damaged or harmful cellular components.1
When optimally regulated, autophagy has been shown to
be cardioprotective.2 In patients undergoing cardiac
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The Journal of Thoracic and Cardiovascular Surrisk scores and crossclamp times are correlated to
alterations in autophagy flux during surgery.3 Impaired
autophagy has been shown to result in unfavorable cardiac
remodeling and increased rates of postoperative atrial
fibrillation in patients undergoing cardiac surgery.4 In
cardiac myocytes, autophagy is upregulated as a result of
cellular stress from hypoxia and chronic ischemia and is
significantly downregulated in the setting of caloric excess
and metabolic syndrome (Figure 1). Several physiologic
pathways affect autophagy signaling and induction. When
autophagy is induced, a double-membrane ‘‘C’’-shaped
structure is formed and closes, resulting in an autophago-
some. The autophagosome fuses with a lysosome forming
an autophagolysosome, which ultimately envelops and
removes unfavorable cellular components, such as damaged
organelles and accumulated amino acids2,5 (Figure 1).
Although autophagy in excess may lead to cell death,
when appropriately regulated, autophagy allows for cellular
salvage and repair, in contrast to apoptosis and necrosis.4,6,7
Thus, exploring therapies that may favorably affect
autophagy are of special interest in the heart, where
cardiomyocytes have a limited capacity for regeneration.
A number of novel and commonly used medications havegery c December 2014
Abbreviations and Acronyms
IM ¼ ischemic myocardium
LAMP-2 ¼ lysosome-associated membrane protein 2
LC3B-I ¼ light chain 3B-I
LC3B-II ¼ light chain 3B-II
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OC ¼ regular diet control group
OHC ¼ high cholesterol control group
OHCS ¼ high cholesterol control group
supplemented with daily oral
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Sbeen reported to regulate autophagy in the heart, including
resveratrol, rapamycin, and statins.2,8,9
Statins are of particular interest given their vast clinical use
and significant cardioprotective effects.10-12 They have been
clearly shown to reduce morbidity and mortality in patients
with coronary artery disease, and there is increasing
evidence that perioperative statin use is associated with a
significant reduction in major adverse outcomes after
cardiac surgery.11-16 In recent years, statin use has been
demonstrated to regulate autophagy activity in tumor cells,
vascular endothelial cells, and cardiac cells.17-19 Statins also
have been shown to affect angiogenesis by promoting
endothelial cell growth and migration, although the
mechanism remains under investigation.20 In a large animal
model, we previously demonstrated that atorvastatin modu-
lates myocardial angiogenesis, despite increasing oxidative
stress in the setting of chronic ischemia.21 These findings sug-
gest a compensatory intracellular response preventing oxida-
tive damage to endothelial cells, such as autophagy.
It is important to note that many of the aforementioned
studies have been performed in small, relatively healthy
animal models. Although these studies are important, they
are often difficult to translate in a clinically relevant
manner. Given the increase in obesity and diabetes, we
have been using a large animal (porcine) model of
metabolic syndrome to better mimic the complex
patients seen in the population with cardiac disease.22,23
Although no animal model perfectly represents human
pathophysiology, pigs have similar hemodynamics, drug
pharmacokinetics, and cardiac anatomy. Also, pig hearts
have similar coronary circulation and, like humans, lack
preexisting collateral vessels and spontaneously develop
atherosclerosis.24 Thus, to further investigate the effects
of atorvastatin on autophagy, we used a clinically relevant,
porcine model of metabolic syndrome and chronic
myocardial ischemia. We hypothesized that atorvastatin
would prevent the inhibition of autophagy resulting from
a high-fat diet leading to metabolic syndrome.The Journal of Thoracic and CarMATERIALS AND METHODS
Animal Model and Surgical Interventions
Ossabaw swine (Purdue Ossabaw Facility, Indiana University,
Indianapolis, Ind) were divided into 3 groups based on a daily diet fed
over a 14-week period. The regular diet control group (OC, n ¼ 8) was
fed a diet consisting of ‘‘regular’’ chow. The high cholesterol control group
(OHC, n¼ 8) was given daily feedings of 500 g of a high cholesterol diet as
previously described.21 Animals in the experimental group were fed the
same diet as the OHC animals but were supplemented with daily oral
atorvastatin (1.5 mg/kg/d; OHCS, n¼ 8) (Pfizer Inc, New York, NY). After
14 weeks, animals underwent surgical placement of a titanium ameroid
constrictor (Research Instruments SW, Escondito, Calif) on the proximal
left circumflex coronary artery. Six months after ameroid placement, the
animals were euthanized and their hearts were harvested.Myocardial tissue
collected from chronically ischemic myocardium (IM) and nonischemic
myocardium (NIM) was rapidly frozen in liquid nitrogen. Tissues used
for analysis in this study are from animals that were reported in our
previous study.21 The methods for weight measurements, dextrose
challenge, anesthesia, and surgical interventions have been described.21
All experiments were approved by the Institutional Animal Care and Use
Committee of the Rhode Island Hospital. Animals were cared for in
compliance with the Principles of Laboratory Animal Care formulated
by the National Society for Medical Research and the Guide for the Care
and Use of Laboratory Animals.
Protein Expression
Protein lysates were prepared from NIM and IM. Lysate preparation,
Western blotting, image capture, and band quantification methods were
performed as previously described. Lysates transferred to polyvinylidene
difluoride membranes (Millipore, Bedford, Mass) were incubated
overnight at 4C in primary antibodies at dilutions recommended by the
manufacturer. Primary antibodies used were mammalian target of
rapamycin (mTOR), Beclin-1, light chain 3B-I (LC3B-I), light chain
3B-II (LC3B-II) (all from Cell Signaling Technology, Danvers, Mass),
and lysosome-associated membrane protein 2 (LAMP-2) (Life
Technologies, Grand Island, NY). Membranes were incubated with the
appropriate horseradish peroxidase-linked secondary antibody at room
temperature for approximately 1 hour (Jackson ImmunoResearch
Laboratories Inc, West Grove, Pa). All membranes were probed with
glyceraldehyde 3-phosphate dehydrogenase (Cell Signaling Technology)
to correct for protein loading error.
Data Analysis
AllWestern blot results are expressed as fold change standard error of
the mean compared with OC. The Western blot bands were quantified
with densitometry using Image-J software (National Institutes of Health,
Bethesda, Md). P values for the Western blot data are reported from a




Animals included for analysis survived to the completion
of the study.When compared with animals fed a regular diet
(OC), animals fed a high-fat diet (OHC and OHCS) had a
significant increase in weight from the time of ameroid
placement to the time of harvest and significantly elevated
glucose levels 30 minutes after an intraoperative dextrose
challenge (P< .001, P ¼ .011, respectively) (Figure 2).
As previously published, capillary density and arteriolar
density were significantly increased in the OHCS groupdiovascular Surgery c Volume 148, Number 6 3173
FIGURE 1. Schematic model of autophagy in the setting of cardiomyocyte stress.




Scompared with the OHC group. Despite this, there was
no significant difference in myocardial perfusion or
microvessel reactivity.21Western Blots
Nonischemic myocardium. In NIM, animals in the OHC
group had a relative increase in the autophagy flux marker
P62 with a significant increase in the autophagy inhibitory
protein mTOR (P ¼ .017) compared animals in the OC
group. Animals in the OHC group also had an accumulation
in several proteins essential for autophagy, including
Beclin-1, LC3B-I, and LCB-II (P ¼ .025, P<.0001, and
P ¼ .0012, respectively) (Table 1, Figure 3). Of note,
atorvastatin supplementation prevented these changes as
demonstrated by a decrease in autophagy flux marker P62
(0.0056) and a decrease in mTOR (P ¼ .017) in the
OHCS group compared with the OHC group. Animals inFIGURE 2. Weight increase (kilograms) and blood glucose after dextrose challe
error of the mean. Weights were measured before ameroid placement and again
dextrose challenge (50 mg/kg). One-way analysis of variance performed to d
OC, Regular diet control group; OHC, high cholesterol control group; OHCS, hig
3174 The Journal of Thoracic and Cardiovascular Surthe OHCS group also had a relative decrease in Beclin-1
with a significant decrease in LC3B-I and LCB-II
(P<.001 and P ¼ .0012, respectively) (Table 1, Figure 3)
compared with the OHC group.
Ischemic myocardium. In the IM, atorvastatin had the
opposite effect, with a decrease in autophagy flux as
indicated by an increase in p62 (P ¼ .0021) and an
accumulation of LC3B-I (0.012), LCB-II, and LAMP-2
(P ¼ .012, P ¼ .057, and P ¼ .0095, respectively)
(Table 1, Figure 3). Of note, neither a high-fat
diet alone nor a high-fat diet with supplemental atorvastatin
significantly affected mTOR signaling (P ¼ .095).DISCUSSION
The results of this study demonstrate that in the setting of
metabolic syndrome, atorvastatin supplementation has dif-
ferential effects on autophagy, such that it is upregulatednge at terminal procedure:Weight change and blood glucose level standard
before harvest. Blood glucose level measured 30 minutes after intravenous
etermine P value. Bonferroni multiple comparison tests were performed.
h cholesterol control group supplemented with daily oral atorvastatin.
gery c December 2014
TABLE 1. Protein expression in myocardium
Targets OC OHC OHCS P value
NIM
P62 1  0.149 1.30  0.211 0.51  0.067 .0056z
mTOR 1  0.110 2.17  0.429 1.09  0.240 .017*,z
Beclin-1 1  0.081 1.74  0.256 1.43  0.145 .025*
LC3B-I 1  0.066 3.04  0.365 1.29  0.135 <.001*,z
LC3B-II 1  0.147 1.86  0.240 0.94  0.085 .0012*,z
LAMP-2 1  0.093 1.12  0.080 0.83  0.115 .13
IM
P62 1  0.053 1.04  0.054 1.54  0.158 .0021y,z
mTOR 1  0.200 0.93  0.129 0.98  0.130 .95
Beclin-1 1  0.248 1.07  0.229 0.86  0.183 .79
LC3B-I 1  0.079 0.58  0.064 1.60  0.358 .012z
LC3B-II 1  0.196 0.45  0.063 1.06  0.246 .057
LAMP-2 1  0.257 0.46  0.067 1.92  0.389 .0095z
Protein expression listed as fold change  standard error of the mean compared with
OC. One-way analysis of variance performed to determine P value. Bonferroni mul-
tiple comparison tests were performed. IM, Ischemic myocardium; LAMP-2,
lysosome-associated membrane protein 2; LC3B-I, light chain 3B-I; LC3B-II, light
chain 3B-II; NIM, nonischemic myocardium; OC, regular diet control group; OHC,
high cholesterol control group; OHCS, high cholesterol control group supplemented
with daily oral atorvastatin; mTOR, mammalian target of rapamycin. *Indicates sig-
nificant difference between the OC and OHC groups. yIndicates significant difference
between the OC and OHCS groups. zIndicates significant difference between the
OHC and OHCS groups.




Sin NIM and downregulated in IM. The perioperative
benefits of statins in patients undergoing cardiac surgery
are significant, yet the underlying mechanisms remain un-
der investigation.12,16 Autophagy has become increasingly
implicated in cardioprotection during cardiac surgery,
and several studies have demonstrated the significant
effects of statins on autophagy.3,4 Significant potential
therapies may be uncovered and optimized as we explore
mechanisms by which statins regulate autophagy.
Autophagy is a complex and dynamic process with
several points of regulation. It has become widely accepted
that alterations in autophagy can be determined through the
measurement of several regulatory protein markers.3,5,8 In
particular, measuring alterations of P62 has been used as
an index of autophagy flux.25 In response to different
stressors or stimuli, P62 can be altered within minutes.3
We found that animals given a high-fat diet had an increase
in regulatory markers of autophagy, including Beclin-1,
LC3B, and LAMP2. These findings alone could suggest
an increase in autophagy or a decrease in autophagy,
because these proteins accumulate in the setting of
decreased autophagy. However, measuring the autophagy
flux marker P62 allows for a more clear understanding of
the results. Given that P62 is degraded by the activation
of autophagy, we can assume that the increase in P62 in
this setting is a result of diminished autophagy. Further
supporting this finding is the increase of mTOR. A known
inhibitor of autophagy, mTOR has been demonstrated to
be upregulated in the setting of caloric excess.8,9 In theThe Journal of Thoracic and CarNIM, atorvastatin prevented these changes, resulting in an
overall increase in autophagy.
In the IM, atorvastatin had a different effect, resulting in a
relative decrease in autophagy as demonstrated by an
increase in P62 and other regulatory proteins, including
LC3B-I, LC3B-II, and LAMP-2. It remains unclear why
atorvastatin had these differential effects in IM versus
NIM. Further elucidating a reason for this difference may
help provide insight into how statins improve outcomes in
patients with coronary artery disease and how perioperative
statin use can be optimized for cardioprotection. This differ-
ence suggests alternative mechanisms by which statins
affect autophagy, depending on the stimulus and environ-
ment. Perhaps animals that were already receiving statin
therapy had increased resistance to the stress of ischemia,
resulting in a relative decreased need for autophagy to
remove harmful by-products in the IM. Another possibility
is that ischemic stress results in an overexpression of
autophagy markers, and statin therapy helps maintain an
appropriate homeostatic balance in the setting of increased
oxidative stress and cell death. Indeed, autophagy in excess
and impaired clearance of autophagosomes have been
demonstrated to contribute to cardiomyocyte death.26,27
Mechanisms by which statins regulate autophagy remain
under investigation. Several studies have demonstrated that
the various forms of statins appear to have similar effects
on autophagy through the inhibition of mTOR.18,28,29 Of
note, inhibition of mTOR activity has been shown to impair
angiogenesis,30 whereas prolonged mTOR activity can lead
to vascular dysfunction.31 Sinha and colleagues32 demon-
strated that inhibition of mTOR activity improves coronary
microvascular flowafter cardiac transplantation.During early
stages of atherosclerosis, there is evidence that statins
enhance autophagy through inhibition of mTOR, resulting
in stabilization of coronary plaques through autophagy-
mediated macrophage depletion and inhibition of cell death.
In contrast, ‘‘mTOR independent autophagy’’ has been
associated with increased inflammation and coronary plaque
progression and instability.28,33 As already mentioned, in our
current study, atorvastatin therapy regulated mTOR
expression in the NIM, whereas in the IM there was no
significant difference in mTOR regulation among the 3
groups. The stressful stimuli associated with chronic
ischemia may have resulted in an overwhelming and
relatively equivalent effect on mTOR signaling, regardless
of diet modification. Again, this suggests a different
mechanism for autophagy regulation in the IM that is
mTOR independent. Alternate mechanisms by which
statins may affect autophagy in an mTOR-independent
manner are likely and merit further investigation.
Study Limitations
Foremost, we are unable to comment on differences in
treatment length or dose-dependent responses becausediovascular Surgery c Volume 148, Number 6 3175
FIGURE 3. Protein expression in myocardium fold change  standard error of the mean compared with OC. One-way analysis of variance performed to
determine P value. Bonferroni multiple comparison tests were performed. LAMP-2, Lysosome-associated membrane protein 2; LC3B-I, light chain 3B-I;
LC3B-II, light chain 3B-II; mTOR, mammalian target of rapamycin; OC, regular diet control group; OHC, high cholesterol control group; OHCS, high
cholesterol control group supplemented with daily oral atorvastatin.




Streatment length and atorvastatin doses were fixed. Because
autophagy is a dynamic process, it is important to note that
levels of autophagy markers may differ from our current
results if tissue was analyzed at different time-points.
Indeed, this is a limitation when using a large animal model,
in which the least number of animals are used to achieve
adequate power. It is also important to note that we did3176 The Journal of Thoracic and Cardiovascular Surnot directly measure autophagy activity. The gold standard
for directly measuring autophagy is by directly visualizing
the autolyosome at different stages of its development.
Because autophagy is a ubiquitous process and the
autolysosome easily can be mistaken for other structures,
electron microscopy would not allow any reasonable means
to objectively and reproducibly quantify the process. Thesegery c December 2014




Sare known criticisms for using electron microscopy. Thus,
as has been described by our group and others,3,5,8 we
used Western blotting to measure specific and essential
markers of the process. Although this method is an
indirect measure of autophagy, it allows for the objective
measurement and reproducibility necessary to conduct a
study of this nature.
Further complicating the study of statins is the known
dose-dependent effects of this statins. Urbich and
colleagues34 demonstrated that atorvastatin has differential
dose-dependent effects on endothelial cell migration and
angiogenesis, where lower doses resulted in improved
indicators of angiogenesis and higher doses resulted in
prevention of migration through endothelial cell apoptosis.
We have also noted a dose-dependent effect of atorvastatin
on indicators of angiogenesis, where a lower dose of
atorvastatin resulted in an upregulation of proangiogenic
proteins along with increased capillary and arteriolar
densities, and higher doses of atorvastatin did not improve
angiogenic response.21,35 In the current study, we again
used a relatively lower dose than in our prior studies,
giving 1.5 mg/kg of atorvastatin. However, this is still a
relatively high dose of atorvastatin, and an even lower
dose may have exposed different effects.
CONCLUSIONS
This represents the first study in a large animal model to
demonstrate the effects of atorvastatin on autophagy in
chronic myocardial ischemia. Of note, and distinct from
many other animal studies, this study was performed in
animals provided with several months of a high-fat diet
resulting in significantly increased weight gain and signs
of insulin resistance (Figure 2). Given the continued
increase in obesity and diabetes, and the widespread use
of statins, this study highlights important effects of statins
in a clinically relevant large animal model. The findings
of this study may have implications regarding the purported
protective role of statin drugs in the setting of cardiac
surgery. Further investigation into the effects of statins on
autophagy in IM and NIM is warranted.
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Cardiovasc Surg. 2006;132:1299-306.MMENTARYCardiac cannibalismAlden H. Harken, MD, FACSSo, if you and a couple of guys are floating on a life raft in
the middle of the Pacific and you are running out of food,
what do you do? You throw the guy who eats the most
overboard. Unless, of course, you can swallow both your
pride and the big guy’s liver. As it turns out, Drosophila
figured out both of these steps millions of years ago .
and autophagy has been evolutionarily conserved ever
since. This remarkable self-preservation strategy is
activated by both starvation and stress.
Autophagy is a catabolic mechanism of degrading and
disposing of dysfunctional cellular elements. Broken or
profligate cytoplasmic constituents are herded into and
isolated in a double-membraned vesicle imaginatively
termed an autophagosome. This vesicle then fuses with a
toxic, enzyme-laden lysosome, which spews its contents
into the autophagosomal recycling container. The
component parts of the previously worn-out cytoplasmic
scaffolding can then be used to rebuild essential
cellular machinery. But—like many good things—the
autophagosome can go rogue and begin eating things that
are not on the menu.In the study described in their article in this issue of the
Journal of Thoracic and Cardiovascular Surgery, Sabe and
colleagues1 from the Sellke laboratory fed Ossabaw pigs a
regular diet, a high-cholesterol diet, or the same
high-cholesterol pa^te plus a statin. The lipid-laden diet
contained a ‘‘high-cholesterol’’ formula consisting of 4%
cholesterol, 17.2% coconut oil, 2.3% corn oil, 1.5%
sodium cholate, and 75% regular chow.2 Let’s place this in
perspective: a McDonald’s Double Quarter Pounder With
Cheese provides 277 grams of enjoyment with 749 calories,
42 grams of fat, and 165 mg of cholesterol.3 So the pudgy
pigs in this study got the equivalent of a couple of
Quarter Pounders a day and probably thought they were
starving. And these pigs paid the price of cholesterol-
boosting gluttony with an associated decrease in protective
autophagy.
Interestingly, atorvastatin (not available to most pigs)
preserved this highly-conserved evolutionary myocellular
protective mechanism in nonischemic myocardium.
Perhaps surprisingly, a statin had the opposite effect in the
ischemic heart.
Several aspects of this important article are fasci-
nating: (1) for those of us type A cardiac surgical as-
cetics who are capable of sticking to a lifetime
relatively healthy diet, in only 14 weeks of binge eating,
we can blow the whole thing; (2) statins, which block
the rate-limiting step in cholesterol synthesis, are also
termed pleiotropic (which means that they also do lots
of stuff that we don’t understand); (3) for healthy non-
ischemic myocardium, autophagy seems to be an effec-
tive depository for component recycling and energy; and
(4) a cardiomyocellular autophagosome in a male Ossa-
baw pig is kind of like the garbage disposal in the
kitchen of a recycling center run by solar panels on
the roof.gery c December 2014
